First Choice Neurology

Channa Kolb-Sobieraj, MD

Channa Kolb-Sobieraj, MD

Channa Kolb-Sobieraj, MD
Channa Kolb-Sobieraj, MD
is a board-certified neurologist who specializes in Multiple Sclerosis. Dr. Kolb-Sobieraj is board-certified in neuroimaging and has completed an MS Fellowship at the Brigham and Women’s Hospital/Harvard Medical School. She has been involved in numerous academic research clinical trials with a special interest in MS therapeutics and environmental influences on disease. Dr. Kolb-Sobieraj has a special interest in incorporating a comprehensive multidisciplinary approach to patient care. In addition to treating Multiple Sclerosis patients, Dr. Kolb-Sobieraj also cares for general neurology patients.

Schedule Appointment




Multiple Sclerosis, Neurology

Board Certifications
Neurology, Neuroimaging

Medical Interests
Multiple Sclerosis, Neurology

University at Buffalo School of Medicine and Biomedical Sciences

Cleveland Clinic, Florida

Harvard Medical School, Brigham and Women’s Hospital: Multiple Sclerosis and Neuroimmunology
University at Buffalo School of Medicine and Biomedical Sciences: Neuroimaging

American Academy of Neurology

Awards & Accolades
MS Fellowship Director, July 2021-August 2022.
Recipient of the 2015 Louis A. and Ruth Siegal Award, honorable mention for excellence in teaching.
Clinical abstract presentation was awarded "Highlights in the Field at the 65th AAN Annual Meeting", poster presentation, March 2013 in the section of Autonomic and Clinical Neurophysiology.

Research, Clinical Trials & Publications


1. Benedict RH, Pol J, Yasin F, Hojnacki D, Kolb C, Eckert S, Tacca B, Drake A, Wojcik C, Morrow SA, Jakimovski D, Fuchs TA, Dwyer MG, Zivadinov R, Weinstock-Guttman B. Mult Scler. Recovery of cognitive function after relapse in multiple sclerosis. 2020 Jan 23:1352458519898108. doi: 10.1177/1352458519898108. Online ahead of print.PMID: 31971066

2. Fuchs TA, Ziccardi S, Benedict RHB, Bartnik A, Kuceyeski A, Charvet LE, Oship D, Weinstock-Guttman B, Wojcik C, Hojnacki D, Kolb C, Escobar J, Campbell R, Tran HD, Bergsland N, Jakimovski D, Zivadinov R, Dwyer MG. Functional Connectivity and Structural Disruption in the Default-Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis. J Neuroimaging. 2020 Jul;30(4):523-530. doi: 10.1111/jon.12723. Epub 2020 May 11.PMID: 32391981

3. Jakimovski D, Zivadinov R, Bergsland N, Ramasamy DP, Hagemeier J, Weinstock-Guttman B, Kolb C, Hojnacki D, Dwyer MG. Sex-Specific Differences in Life Span Brain Volumes in Multiple Sclerosis. J Neuroimaging. 2020 May;30(3):342-350. doi: 10.1111/jon.12709. Epub 2020 May 11.PMID: 32392376

4. Genovese AV, Hagemeier J, Bergsland N, Jakimovski D, Dwyer MG, Ramasamy DP, Lizarraga AA, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R. Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. Radiology. 2019 Nov;293(2):424-433. Doi: 10.1148/radiol.2019190306. Epub 2019 Sep 24.PMID: 31549947

5. Zivadinov R, Ramanathan M, Hagemeier J, Bergsland N, Ramasamy DP, Durfee J, Kolb C, Weinstock-Guttman B. Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. Mult Scler Relat Disord. 2019 Sep 9;36:101388. doi: 10.1016/j.msard.2019.101388. PMID: 31525628

6. Zivadinov R, Bergsland N, Hagemeier J, Ramasamy DP, Dwyer MG, Schweser F, Kolb C, Weinstock-Guttman B, Hojnacki D. Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. Neurology. 2019 Aug 6;93(6):e611-e623. doi: 10.1212/WNL.0000000000007892. Epub 2019 Jul 8. PMID: 31285398

7. Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D, Weinstock-Guttman B. Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. J Clin Med. 2019 Mar 12;8(3). pii: E344. doi: 10.3390/jcm8030344. PMID: 30870983

8. Sternberg Z, Podolsky R, Nir A, Yu J, Nir R, Halvorsen SW, Chadha K, Quinn JF, Kaye J, Kolb C. Increased free prostate-specific antigen serum levels in Alzheimer's disease, correlation with Cognitive Decline. J Neurol Sci. 2019 May 15;400:188-193. doi: 10.1016/j.jns.2019.04.006. Epub 2019 Apr 5. PMID: 30981123

9. Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R. Aging and Brain Atrophy in Multiple Sclerosis. J Neuroimaging. 2019 Jul;29(4):527-535. doi: 10.1111/jon.12625. Epub 2019 May 10. PMID: 31074192

10. Gandhi S, Marr K, Mancini M, Caprio MG, Jakimovski D, Chandra A, Hagemeier J, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R. No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5 years. BMC Neurol. 2019 Jun 11;19(1):121. doi: 10.1186/s12883-019-1350-2. PMID: 31185944

11. Satchidanand N, Drake A, Smerbeck A, Hojnacki D, Kolb C, Patrick K, Weinstock-Guttman B, Motl R, Benedict RH. Dalfampridine benefits ambulation but not cognition in multiple sclerosis. Mult Scler. 2018 Dec 19:1352458518815795. PMID: 30566030

12. Vaughn C, Bushra A, Kolb C, Weinstock-Guttman B. An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis. CNS Drugs. 2018 Feb;32(2):161-178. doi: 10.1007/s40263-018-0496-6. Review. PMID:29508244

13. Zivadinov R, Bergsland N, Hagemeier J, Tavazzi E, Ramasamy DP, Durfee J, Cherneva M, Carl E, Carl J, Kolb C, Hojnacki D, Weinstock-Guttman B. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study. J Neurol Sci. 2018 Apr 15;387:152-156. doi: 10.1016/j.jns.2018.02.023. Epub 2018 Feb 10. PMID: 29571854

14. Zivadinov R, Tavazzi E, Hagemeier J, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B. The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. CNS Drugs. 2018 May 16. doi: 10.1007/s40263-018-0521-9. PMID: 29767815

15. Zivadinov R, Tavazzi E, Bergsland N, Hagemeier J, Lin F, Dwyer MG, Carl E, Kolb C, Hojnacki D, Ramasamy D, Durfee J, Weinstock-Guttman B, Schweser F. Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. Radiology. 2018 Jul 17:180136. doi: 10.1148/radiol.2018180136. PMID: 30015589

16. Zivadinov R, Ramasamy DP, Hagemeier J, Kolb C, Bergsland N, Schweser F, Dwyer MG, Weinstock-Guttman B, Hojnacki D. Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis. AJNR Am J Neuroradiol. 2018 Feb 8. doi: 10.3174/ajnr.A5541. PMID 29439125

17. 8. Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-Guttman B. Interferon β for Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018 Jan 8. pii: a032003. doi: PMID 29311124

18. Sternberg Z, Kolb C, Chadha K, Nir A, Nir R, George R, Johnson J, Yu J, Hojnacki D. Fingolimod anti-inflammatory and neuroprotective effects modulation of RAGE axis in multiple sclerosis patients. Neuropharmacology. 2018 Mar 1;130:71-76. PMID 29197515

19. Jakimovski D, Weinstock-Guttman B, Ramanathan M, Kolb C, Hojnacki D, Minagar A, Zivadinov R. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. Expert Opin Biol Ther. 2017 Sep;17(9):1163-1172. doi: 10.1080/14712598.2017.1347632. PMID: 28658986

20. Kappus N, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Carl E, Ramasamy DP, Cherneva M, Durfee J, Bergsland N, Dwyer MG, Kolb C, Hojnacki D, Ramanathan M, Zivadinov R. Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):181-7. PMID 25722366

21. Sternberg Z, Sternberg D, Chichelli T, Drake A, Patel N, Kolb C, Chadha K, Yu J, Hojnacki D. High-mobility group box 1 in multiple sclerosis. Immunol Res. 2016 Apr;64(2):385-91. doi: 10.1007/s12026-015-8673-x. PMID 2610098

22. Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Bandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Squreshi, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016;87:885-889.

23. Gandhi S, Jakimovski D, Ahmed R, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R. Use of natalizumab in multiple sclerosis: current perspectives. Expert Opin Biol Ther. 2016 Sep;16(9):1151-62. doi: 10.1080/14712598.2016.1213810. PMID: 27413840

24. Zivadinov R, Ramasamy DP, Benedict RR, Polak P, Hagemeier J, Magnano C, Dwyer MG, Bergsland N, Bertolino N, Weinstock-Guttman B, Kolb C, Hojnacki D, Utriainen D, Haacke EM, Schweser F. Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study. Radiology, 2016 Dec;281(3):884-895. Epub 2016 Jun 16. PMID: 27308776 PMID: 27308776

25. H. Kamal, C. Kolb, S. Eckert, A. Arora, N, Silvestri, G. Wolfe. Recurrent Miller Fisher Syndrome. Journal of Clinical Neuromuscular Disease, 2016;17(3):16.

26. Kappus N, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Carl E, Ramasamy DP, Cherneva M, Durfee J, Bergsland N, Dwyer MG, Kolb C, Hojnacki D, Ramanathan M, Zivadinov R. Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry, 2015 Feb 26. PMID: 25722366

27. E. Grazioli, C. Kolb, B. Weinstock-Guttman, “Temporal and Clinical course of Multiple Sclerosis”, in Primer on Multiple Sclerosis, B. Geisser, Ed. New York: Oxford University Press, 2015.

28. Teter B., Kavak K., Kolb C., Coyle P., Weinstock-Guttman B. Parity Associated with Long-Term Disease Progression in Women with Multiple Sclerosis. J Mult Scler, 2014 1:101. doi:10.4172/2376-0389.1000101

29. Kolb-Sobieraj C., Gupta S., Weinstock-Guttman B. Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review. Neurol Ther, 2014 Jun; 3(1): 29–39.

30. C. Kolb, S. M. Faheem, B. Weinstock-Guttman,“ The role of nutritional Factors and Multiple Sclerosis”, in Metabolic Medicine and Surgery, M. Rothkopf, and M. Nusbaum, EDs. Boca Raton: Taylor & Francis, 2013.

31. Houtchens M.K., Kolb C.M. Multiple Sclerosis and Pregnancy: Therapeutic Considerations. Journal of Neurology, 2012.

Clinical Trials:
1. Evaluating the emotional loss and distress and its relationship to resilience in caregivers of persons with MS. Sponsor: Internal UB

2. DELIVER-MS: Determining the Effectiveness of early Intensive Versus Escalation approaches for the treatment of Relapsing-Remitting Multiple Sclerosis. Sponsor: PCORI via subaward from CCF.

3. ENLIGHTEN: A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod. Sponsor: Celgene.

4. EXCHANGE: Exploring the safety and tolerability of conversion from oral, injectable or infusion disease-modifying therapies to dose-titrated Oral Siponimod (Mayzent®) in patients with advancing forms of relapsing multiple sclerosis: A 6-month open-label, multi-center Phase IIIb study. Sponsor: Novartis

5. EXPERIENCE-US Study: A Prospective, Observational Study Evaluating Persistence on Treatment, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World Setting. Sponsor: Biogen

6. Feasibility of the Multiple Sclerosis Performance Test for assessment of functional performance measures in patients with Multiple Sclerosis. Sponsor: Biogen

7. Natalizumab for Prevention of Post-Partum Relapses in Patients with Multiple Sclerosis. Sponsor: Biogen

Past Studies:

1. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis. Sponsor: ITN.

2. DECIDE: Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus AVONEX® (Interferon β-1a) in Patients with Relapsing-Remitting Multiple Sclerosis. Sponsor: Biogen.

3. EXTEND: A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects with Multiple Sclerosis Who Have Completed Study 205MS301. Sponsor: Biogen.

4. ENDORSE: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis. Sponsor: Biogen.

5. STRATIFY-2 : Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri®. Sponsor: Biogen.

6. ASSESS: A 12-Month, Randomized Rater-And Dose-Blinded Study To Compare The Efficacy And Safety Of Fingolimod .25mg And 0.5mg Administered Orally Once Daily With Glatiramer Acetate 20mg Administered Subcutaneously Once Daily In Patient With Relapsing-Remitting Multiple Sclerosis. Sponsor: Novartis.

7. TERIPRO: A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients. Sponsor: Genzyme.

8. SPI2: Effect of MD1003 in progressive multiple sclerosis: a randomized double-blind placebo-controlled study. Sponsor: MedDay.

Accepts New Patients

List of insurance plans accepted


9970 Central Park Boulevard, Suite 207
Boca Raton, FL 33428
Phone: (561) 482-1027
Fax: (561) 482-1028

2605 W. Atlantic Avenue, Suite C-102
Delray Beach, FL 33445
Phone: (561) 482-1027
Fax: (561) 482-1028

Monday – Friday
8:30 a.m. – 5:00 p.m.



Channa Kolb-Sobieraj, MD is a neurologist in Boca Raton and Delray Beach, Florida. You can contact her office for an appointment at (561) 482-1027.

Translate »
Skip to content